2. Signaling Pathways
  3. Immunology/Inflammation
  4. Glycoprotein VI

Glycoprotein VI

GPVI

Glycoprotein VI (GPVI) is a membrane glycoprotein unique to platelets and has been identified as a physiological receptor for collagen. Damage to a vessel wall exposes the subendothelial component collagen to platelets in the blood flow. Interaction of platelets with collagen via the receptor GPVI results in platelet activation and adhesion--the processes that are essential for thrombus formation. On the platelet surface, GPVI is present as a complex with the homodimeric Fc receptor y-chain (FcRgamma with a possible stoichiometry of two GPVI molecules and one FcRgamma dimer). When collagen binds to GPVI, a platelet activation cascade is initiated by tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif of FcRgamma and this phosphorylation induces the formation of a large complex composed from many signal-transducing proteins. In flow adhesion experiments that closely approximate physiological conditions, GPVI is essential for the formation of large platelet aggregates on collagen.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99013
    Codrituzumab
    		Inhibitor 99.07%
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
    Codrituzumab
  • HY-P99644
    ACT017
    		Inhibitor 99.00%
    ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke.
    ACT017
  • HY-P10888A
    GPC3 targeting peptide 1 TFA
    		99.40%
    GPC3 targeting peptide 1 TFA is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
    GPC3 targeting peptide 1 TFA
  • HY-144390
    (S)-S007-1558
    		99.78%
    (S)-S007-1558 (compound 5) is a glycoprotein VI (GPVI) platelet receptor antagonist. (S)-S007-1558 inhibits collagen-induced platelet aggregation with an IC50 of 25.3 μM.
    (S)-S007-1558
  • HY-P990840
    Anti-GPC3 Antibody (YP7)
    		Inhibitor
    Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC3. Anti-GPC3 Antibody (YP7) reacts with the C-lobe of cell surface-associated glypican-3 (GPC3). Anti-GPC3 Antibody (YP7) can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
    Anti-GPC3 Antibody (YP7)
  • HY-P992011
    CAT-07
    		Inhibitor
    CAT-07 is an anti-human GPC3/Glypican 3 antibody. CAT-07 can be used for the research of cancer, such as hepatocellular carcinoma.
    CAT-07
  • HY-P992457
    SAR444200
    SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3+ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma.
    SAR444200
  • HY-P11618
    10P3Me
    		Ligand
    10P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions.
    10P3Me
  • HY-W1124925
    DOTA-GPC3 targeting peptide 2
    		Ligand 98.83%
    DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements.
    DOTA-GPC3 targeting peptide 2
  • HY-P990841
    Anti-pan-Glypican Antibody (HS20)
    		Inhibitor 99.44%
    Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
    Anti-pan-Glypican Antibody (HS20)
  • HY-125053A
    Batifiban TFA
    		Antagonist 99.70%
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
    Batifiban TFA
  • HY-P990842
    Anti-GPC-2 Antibody (CT3)
    		Inhibitor
    Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1 κ chimeric antibody, targeting to human GPC-2. Anti-GPC-2 Antibody (CT3) reacts with tumor-associated exons 3 and 10 of glypicans-2 (GPC2). Anti-GPC-2 Antibody (CT3) can be used for the research of cancer, such as neuroblastoma.
    Anti-GPC-2 Antibody (CT3)
  • HY-115912
    GPVI antagonist 3
    		Antagonist
    GPVI antagonist 3 (Compound 2) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 3 are, respectively, 1.01 μM for collagen, 1.92 μM for CRP, 7.24 μM for convulxin and 51.74 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 3 is a promising antiplatelet agent.
    GPVI antagonist 3
  • HY-P10949
    pep-10L peptide
    		Antagonist
    Pep-10L peptide is a glycoprotein VI (GPVI) antagonist with Ki values of 180, 225, and 179 μM for CPR, GPO-1, and Type 1 collagen, respectively. Pep-10L peptide has anti-thrombotic effects.
    pep-10L peptide
  • HY-115911
    GPVI antagonist 2
    		Antagonist 99.24%
    GPVI antagonist 2 (Compound 1) is a potential antagonist of Glycoprotein VI (GPVI). IC50 values of GPVI antagonist 2 are, respectively, 0.35 μM for collagen, 0.80 μM for CRP, 195.2 μM for convulxin and 81.38 μM for thrombin. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic research. GPVI antagonist 2 is a promising antiplatelet agent.
    GPVI antagonist 2
  • HY-125615
    DMP 728 methanesulfonate
    		Antagonist
    DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries.
    DMP 728 methanesulfonate
  • HY-P991448
    MDX-1414
    		Inhibitor
    MDX-1414 is a human IgG1 monoclonal antibody (mAb) targeting GPC3. MDX-1414 has antitumor activity in the HepG2 xenograft model. MDX-1414 can be used in liver cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
    MDX-1414
  • HY-P10888
    GPC3 targeting peptide 1
    GPC3 targeting peptide 1 is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
    GPC3 targeting peptide 1
Cat. No. Product Name / Synonyms Application Reactivity